Gapping down
In reaction to disappointing earnings/guidance:
- REVG -18.7%, AMSC -12.9%, SJM -8.5%, CLDR -6.9%, THO -6.5%, MDB -3.4%, UNFI -3.3%, FGP -1.9%
Other news:
- PTI -28.6% (reports data from ongoing Phase 1 Study of PTI-801 in Cystic Fibrosis patients on background Orkambi therapy)
- MDXG -24.5% (to restate series of historical financial statements, appoints interim CFO)
- ESND -10.6% (following Genuine Parts' S.P. Richards business merger update; notes Staples has not otherwise engaged in discussions with Essendant)
- WGO -6.7% (following THO and REVG earnings/guidance)
- ZYME -5.1% (prices underwritten public offering of 5.4 mln common shares at a price to the public of $15.75 per common share)
- LCII -4.1% (following THO and REVG earnings/guidance)
- DCPH -4.1% (prices underwritten public offering of 4.3 mln shares of its common stock at a public offering price of $40.00 per share)
- CARO -2.9% (agreed to sell 1,500,000 shares of its common stock, and that certain of its executive officers and directors have agreed to sell 96,350 of their shares of the Company's common stock, in an underwritten public offering)
- OPTN -1.4% (prices offering of 5 mln shares of common stock by co and selling share holders at $22.25 per share)
- JCP -1.1% (Moody's downgrades J.C. Penney CFR to B2 from B1 reflecting continued weakness in op performance coupled with uncertainty in its strategic plan given the recent departure of its CEO)
- CWH -1.1% (following THO and REVG earnings/guidance)
- MB -1.1% (proposed private offering of $200 million of convertible senior notes due 2023)
- FNHC -0.9% (files for $150,000,000 mixed securities shelf offering)
- ETR -0.8% (registered underwritten offering of 13,289,037 shares of its common stock at a price to the public of $75.25 per share), .
Analyst comments:
- TRU -3.7% (downgraded to Sell from Neutral at Goldman)
- MT -3.1% (downgraded to Sell from Buy at UBS)
- AAXN -2.9% (downgraded to Neutral from Overweight at JP Morgan)
- FSLR -2.5% (downgraded to Sell from Neutral at Goldman )
- GHL -2.4% (downgraded to Underperform from Mkt Perform at Keefe Bruyette)